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Abstract
Background: The integral membrane proteins of neurons and
other excitable cells are generally resistant to high resolution
structural tools. Structure^function studies, especially those
enhanced by the nonsense suppression methodology for unnatural
amino acid incorporation, constitute one of the most powerful
probes of ion channels and related structures. The nonsense
suppression methodology can also be used to incorporate
functional side chains designed to deliver novel structural probes
to membrane proteins. In this vein, we sought to generalize a
potentially powerful tool ^ the tethered agonist approach ^ for
mapping the agonist binding site of ligand-gated ion channels.
Results : Using the in vivo nonsense suppression method for
unnatural amino acid incorporation, a series of tethered quater-
nary ammonium derivatives of tyrosine have been incorporated
into the nicotinic acetylcholine receptor. At three sites a
constitutively active receptor results, but the pattern of activation
as a function of chain length is different. At position K149, there is
a clear preference for a three-carbon tether, while at position K93
tethers of 2^5 carbons are comparably effective. At position
Q55/N57 all tethers except the shortest one can activate the
receptor. Based on these and other data, a model for the receptor
binding site can be developed by analogy to the acetylcholine
esterase crystal structure.
Conclusion: Through the use of nonsense suppression tech-
niques, the tethered agonist approach has been made into a
general tool for probing receptor structures. When applied to the
nicotinic receptor, the method places new restrictions on develop-
ing models for the agonist binding site. ß 2001 Elsevier Science
Ltd. All rights reserved.
Keywords: Tethered agonist ; Nicotinic acetylcholine receptor; Agonist
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1. Introduction
The integral membrane proteins of neurons and other
excitable cells are generally resistant to high resolution
structural tools such as X-ray crystallography and nuclear
magnetic resonance (NMR), making e¡orts to develop
mechanistic insights into their function especially challeng-
ing. Among the most useful approaches has been the com-
bination of site-directed mutagenesis and electrophysiol-
ogy, which allows systematic structure^function studies.
Recently, this capability was greatly enhanced [1,2] by
the adaptation of the nonsense suppression methodology
for unnatural amino acid incorporation [3^5] to the heter-
ologous expression system of the Xenopus oocyte. To date,
over 60 unnatural amino acids have been incorporated
into neuroreceptors and ion channels expressed in living
cells.
An appropriate target for such studies is the nicotinic
acetylcholine receptor (nAChR, Fig. 1). The nAChR fam-
ily of ligand-gated ion channels underlies transmission at
the nerve^muscle synapse and in the autonomic and cen-
tral nervous system [6^8]. It also serves as the target for
nicotine and a number of promising pharmaceuticals for
pain, memory enhancement, and the treatment of Parkin-
son’s disease.
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We are concerned here with the agonist binding site of
the nAChR. Early biochemical studies revealed several key
features of this important region of the receptor. The
nAChR has two binding sites which have been found to
be localized primarily on the K subunits. Pioneering work
by Karlin and colleagues established that a conserved di-
sul¢de bond in the K subunit (Cys 192^193, mouse muscle
numbering) was near the binding site [13]. Photoa⁄nity
labeling studies by Changeux and several radioligand
binding studies [10,15] identi¢ed a large number of aro-
matic residues near the agonist binding site. Later work
implicated residues in the Q and N subunits that may con-
tribute to acetylcholine (ACh) binding [16]. In addition,
Unwin has produced a cryoelectron microscopy image of
the receptor at 4.6 Aî resolution. The cryoelectron micros-
copy reveals extracellular cavities in the two K subunits
that lie above the membrane, about 50 Aî away from the
presumed gate of nAChR ion channel. It has been pro-
posed that these cavities, which are not seen in the other
subunits, represent the agonist binding sites [9]. However,
even with these data, the location and nature of the ago-
nist binding sites in the nAChR are highly debated.
1.1. Tethered agonist approach
We recently used the unnatural amino acid methodol-
ogy to establish that a single residue in each mouse muscle
K subunit, Trp 149, binds an ACh molecule through a
cation^Z interaction [17,18], de¢ning a crucial component
of the agonist binding site [12]. The primary tool was a
comparison of a⁄nities for a series of £uorinated Trp
mutants to their predicted cation^Z binding abilities, the
latter determined by ab initio quantum mechanical calcu-
lations. To further establish Trp 149 as very near the ago-
nist binding site, we incorporated the unnatural amino
acid Tyr-O3Q (Fig. 2) at this position. The side chain of
Tyr-O3Q contains a tethered quaternary ammonium
group that was meant to mimic the analogous functional
group in ACh. Incorporation of Tyr-O3Q at position K149
produced a constitutively active receptor, resulting in nic-
otinic receptor currents even in the absence of ACh.
The tethered agonist strategy has a distinguished history
with the nAChR. In pioneering experiments, tethered ag-
onists were introduced into the nAChR using chemical
modi¢cation of Cys residues created by reduction of the
Cys 192^193 disul¢de bond (see Fig. 1), producing a con-
stitutively active receptor [19,20]. Very recently, Cohen
expanded on this methodology by introducing Cys resi-
dues using site-directed mutagenesis and then reacting
the mutants with various MTS reagents [21]. We will dis-
cuss these results below.
The unnatural amino acid methodology o¡ers an alter-
native and in some ways preferable strategy for introduc-
ing tethered agonists. Since the approach does not rely on
cysteine modi¢cation, the tether can be incorporated at
many di¡erent positions, including sites where the Cys
mutant cannot produce functional receptors, and sites
that are not accessible to external reagents, as might be
expected at a potentially buried agonist binding site. This
strategy also removes ambiguities in tether location that
can arise if more than one cysteine is present in the mol-
ecule and allows a wider variation in functionality. In
Fig. 1. Structural aspects of the nAChR. The global structure is based
on the cyroelectron microscopy of Unwin [9], but with an alternative ar-
rangement of subunits favored by many [10]. Superimposed on the
structure are the multiple ‘loops’ thought to contribute to the agonist
binding site (blue circle with positive charge), with key residues identi-
¢ed. The loop image is an adaptation of a model ¢rst presented by
Changeux [11]. Loops A, B, and C are considered the ‘principal compo-
nents’ of the agonist binding site, while D, E, and F are considered
‘complementary’. Loop E is only implicated in binding curare, not
ACh, but is shown here for consistency with other schemes. Trp K149 is
highlighted as the established cation^Z binding site for ACh [12]. The
‘bracket’ on loop C represents the disul¢de between C192 and C193,
one of the ¢rst regions established to be near the agonist binding site
[13]. The N subunit contains residues that are analogous to those shown
on the Q subunit (Trp N57 and Asp N180), which contribute along with
the other K subunit to the second agonist binding site [14]. This is a
highly schematic image, as the absolute and relative positions of the
loops on the receptor structure remain unknown.
Fig. 2. Structures of ACh and two tethered agonist unnatural amino
acids.
CHBIOL 52 7-2-01 Cyaan Magenta Geel Zwart
48 Chemistry & Biology 8/1 (2001) 47^58
addition, agonist-like functionalities are introduced di-
rectly into the receptor, eliminating possibly deleterious
side reactions associated with chemical modi¢cation strat-
egies.
Here we expand upon our initial observations concern-
ing a tethered agonist in several ways, and thereby estab-
lish the generality of the approach. We describe the novel
synthetic approach to such unnatural amino acids; we
show that varying the tether length produces a variation
in tethered agonist e⁄ciency; and we reveal two other sites
^ Tyr K93 and Trp Q55/N57 ^ where the tethered agonist
strategy is successful. We also discuss the results of incor-
poration of an isosteric but electronically neutral analog of
Tyr-O3Q termed Tyr-O3tBu (Fig. 2), in which the quater-
nary ammonium is replaced by a tert-butyl group. With
these new ¢ndings, a more advanced, but still speculative,
model for the nAChR agonist binding site can be devel-
oped.
2. Results
2.1. Synthesis of Tyr-OnQ and Tyr-O3tBu
For use in the unnatural amino acid methodology, the
synthetic target is the amino acid with the side chain in
place, the amino group protected, and the carboxylate
activated as a cyanomethyl ester [22], which is usually
formed in the ¢nal step. However, this standard strategy
was not successful when applied to a series of amino acids
containing quaternary ammonium side chain groups. In-
stead, we ¢nd that the quaternary ammonium must be
added at the ¢nal stage of the synthesis. A two step ami-
nation sequence is successful despite other potentially sen-
sitive functionalities in the molecule. Fig. 3A summarizes
the successful syntheses of Tyr-OnQ, with n = 2, 3, 4, and
5, followed by coupling with the dinucleotide dCA, which
is a necessary step for unnatural amino acid mutagenesis
[2]. We have also incorporated an isosteric analog of Tyr-
O3Q, Tyr-O3tBu, to probe the role of charge in the func-
tion of the tethered agonists. The synthesis of Tyr-O3tBu
was straightforward and is summarized in Fig. 3B.
Fig. 3. A: Synthetic scheme for Tyr-OnQ. a: NVOC-Cl, Na2CO3, water/dioxane; b: Br-(CH2)n-Br, Cs2CO3, DMF; c: TFA, CH2Cl2 ; d: ClCH2CN,
DMF/DIPEA; e: NaI, acetone; f : NMe3, THF/toluene; g: dCA, DMF, tetrabutylammonium acetate. B: Synthetic scheme for Tyr-O3tBu. h: BH3^
THF, THF; then water, 3 M NaOH, 30% H2O2 ; i : p-toluene sulfonyl chloride, pyridine; j : NVOC-tyrosine t-butyl ester, K2CO3 acetone.
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2.2. Incorporation of Tyr-OnQ into the nAChR
We attempted incorporation of the series of quaternary
ammonium derivatives of tyrosine, Tyr-OnQ (n = 2, 3, 4
and 5), at several positions around the agonist binding
sites of the nAChR, including: Trp K86, Tyr K93, Trp
K149, Trp K184, Tyr K190, Cys K192, Cys K193, Pro
K194, Tyr K198, Trp Q55/N57 and Asp Q174/N180. Thus,
at least one site was probed on each of the ¢ve ‘loops’
(A^D, F) that have been proposed to de¢ne the ACh bind-
ing site (Fig. 1). Given the stoichiometry of the receptor,
suppression in an K subunit incorporates two copies of the
modi¢ed side chain, one associated with each of the two
agonist binding sites of the receptor. For sites in non-K
subunits, we always made two mutations ^ one in Q and
one in the analogous site in N ^ so that both agonist bind-
ing sites are comparably perturbed. Mutant proteins were
expressed in Xenopus oocytes and whole-cell currents were
measured using two-electrode voltage-clamp electrophysi-
ology [2,23,24].
The hallmark of a successful experiment is the observa-
tion of large standing currents in Xenopus oocytes express-
ing the mutant channel in the absence of added ACh (Fig.
4, identi¢ed as a). The standing currents are reduced in the
presence of the open-channel blocker 8-(N,N-diethylami-
no)octyl 3,4,5-trimethoxybenzoate (TMB-8). This estab-
lishes that the observed current is due to a nAChR, rather
than a non-speci¢c basal current in the oocyte. Note that
TMB-8 blocks the channel by binding to the open state of
the receptor in the pore region at a site that is quite far
removed from the agonist binding site. As such, the muta-
tions we are introducing should not impact the ability of
TMB-8 to block constitutive current. In earlier studies
involving Tyr-O3Q at position K149, we also used block-
ade by QX-314 and NMDG; dose-dependent antagonism
by curare; desensitization of the standing current by lon-
ger application of ACh; and single channel measurements
to associate the standing current with the nAChR [12].
In the present work, constitutively active receptors were
observed at only three of the sites evaluated ^ Trp K149,
Tyr K93 and Trp Q55/N57. At the other sites the typical
outcome was that no constitutive current that could be
blocked by TMB-8 was seen. In some cases, very small,
TMB-8 blockable constitutive currents were seen, but only
when the expression level for the receptor was especially
high, as indicated by large ACh-induced currents. We are
reluctant to interpret such small currents. Concerning
these other sites, it is, in general, risky to interpret ‘failed’
nonsense suppression experiments. It could well be that
the unnatural amino acid failed to incorporate into the
protein at the ribosome. Alternatively, ‘failure’ could
mean that the unnatural amino acid was incorporated at
the ribosome, but after incorporation the mutant protein
failed in folding, or assembly, and/or transport to the cell
membrane. Or perhaps receptors containing the tethered
agonists were expressed on the surface of the oocyte, but
the mutant protein is non-functional. Generally it is di⁄-
cult to distinguish among these possibilities, and for the
remainder of this work we will focus on the three sites that
produced constitutively active receptors.
In addition to the channel blocker TMB-8, receptors
were treated with the natural agonist ACh, and in all cases
such treatment led to an increase in current. This estab-
lishes that a tethered quaternary ammonium group is a
fairly weak agonist, a so-called partial agonist, meaning
that full potency is never reached with the tether alone.
Our earlier study [12] showed that, as expected, single
channel conductance for the tethered system is identical
to that of the native receptor, so it is the open probability
that does not reach optimal values. Further supporting
this view, standing currents are only observed when a
mutation of Leu 262 (conventionally referred to as Leu
9P) to Ser is introduced into the channel (M2) region of
the L subunit. Such a mutation is quite far removed from
the agonist binding site and is well established to facilitate
channel opening [12,25,26].
Fig. 4 de¢nes the key parameters for evaluating tethered
agonist experiments. It begins with a standing current that
by convention is considered negative. For the particular
oocyte shown, the value of the standing current (a) was
31200 nA. Application of 5 WM ACh causes a downward
de£ection, indicating an increase in current, and the mag-
nitude of the ACh-induced current is c. After removal of
ACh and reestablishment of a (slightly shifted) baseline,
TMB-8 is added, and the drop in current is labeled b.
Numerically, b is equal to the di¡erence between the
standing current and the current in the presence of
Fig. 4. Representative recording trace (blue) of voltage-clamp currents
for an individual oocyte expressing mutant nAChR with Tyr-O3Q incor-
porated at K149. The red horizontal bars indicate bath application of
ACh (5 WM) and TMB-8 (5 WM). a: Standing current due to constitu-
tively active nAChR; b: standing current that is blocked by TMB-8;
c: ACh-induced current.
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TMB-8. As a gauge of the e¡ectiveness of a given tether in
opening the receptor, we use the ratio of the constitutive
current that is blocked by TMB-8 to the ACh-induced
current (Fig. 4, b/c). This measures the extent to which
the tethered agonist opens the receptor relative to the pre-
sumed maximal response as seen with added ACh. Using
this ratio minimizes complications due to variations in the
expression level of the receptors in Xenopus oocytes. The
larger the b/c ratio, the more e¡ective the tethered agonist.
We appreciate that this is an imperfect measure of the
e¡ectiveness of a tethered agonist, but we consider it to
be a useful qualitative guideline. No quantitative signi¢-
cance is given to the ratios. Fig. 5 summarizes the results
of incorporation of Tyr-OnQ into the nAChR at the three
sites.
2.3. Incorporation of an isosteric, neutral tether
While Tyr-OnQ was designed to deliver a mimic of a
key aspect of ACh ^ the quaternary ammonium group ^ it
remained possible that the agonism seen in these experi-
ments is due to some less speci¢c e¡ect, such as a simple
steric disruption of the agonist binding site. To address
this concern we prepared the isosteric compound of Tyr-
O3Q, where the quaternary ammonium is substituted by a
tert-butyl group (Fig. 2).
We incorporated Tyr-O3tBu at K149, K93 and Q55/N57
sites. We found that incorporation of Tyr-O3tBu at K93
and Q55/N57 does produce constitutively active receptors.
In most cases Tyr-O3tBu is less e¡ective than Tyr-O3Q,
based on both the magnitude of the constitutive currents
(data not shown) and the ratio of the TMB-8-blocked
current to ACh-induced current (Fig. 6).
Upon attempted incorporation of Tyr-O3tBu at K149,
the site at which Tyr-O3Q is most e¡ective, no constitutive
current is observed. In addition, only very small currents
are observed upon application of ACh. This result could
imply that receptors containing Tyr-O3tBu at K149 are
not constitutively active and cannot be activated by ACh
because the tert-butyl compound is obstructing the bind-
ing site. Alternatively, the results could signal that there
are no receptors expressed on the surface of the oocytes.
To discriminate between these two possibilities, further
investigations were undertaken to determine whether
nAChR are indeed expressed on the surface of the oocytes
in the Tyr-O3tBu incorporation experiments. Using either
binding studies on intact oocytes with [125I]bungarotoxin
(a tight-binding antagonist of the nAChR) or Western blot
analyses of oocyte membranes (for experimental details,
see Section 5), we found that indeed more nAChR are
expressed on the surface of the oocyte when Tyr-O3Q is
incorporated than Tyr-O3tBu. In fact, the apparent ex-
pression of Tyr-O3tBu is generally not above background
levels seen in control suppression experiments.
Fig. 5. Tethered agonist relative e⁄ciencies (b/c per Fig. 4) for Tyr-OnQ as a function of n (the number of methylene groups in the side chain) at posi-
tions K149, K93, and Q55/N57. Data shown are for an ACh concentration of 25 WM, although comparable results are seen with other concentrations.
Fig. 6. Results of incorporation of Tyr-O3tBu compared with that of
Tyr-O3Q at three sites of nAChR. The value plotted is the ratio of con-
stitutive current that is blocked by TMB-8 (10 WM) to ACh (25 WM)-in-
duced current, b/c in Fig. 4.
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3. Discussion
The present study shows that the tethered agonist ap-
proach, as implemented by the in vivo nonsense suppres-
sion methodology, is a general tool that can provide val-
uable information about the agonist binding site of a
neuroreceptor. Tethered agonists at three di¡erent sites
give constitutively active receptors. Variations in tether
length can discriminate among the di¡erent sites. In the
particular case of the nAChR, we believe the results have
signi¢cant implications for e¡orts to understand the struc-
ture of this complex protein.
In our preliminary report only Tyr-O3Q at position
K149 was studied. We now ¢nd that tether length signi¢-
cantly in£uences the e¡ectiveness of the agonist at this
position. As shown in Fig. 5, Tyr-O3Q represents the
most e¡ective chain length. Both longer and shorter teth-
ers are signi¢cantly less e¡ective at inducing current ^ Tyr-
O5Q produced no measurable constitutive current. We
interpret this, in part, as a conformational e¡ect. We con-
cluded from our earlier studies that when ACh binds to
the nAChR, the quaternary ammonium group makes van
der Waals contact with the six-membered ring of Trp K149
through a cation^Z interaction [12]. When Tyr-OnQ is
incorporated at K149, its aromatic ring aligns with the
¢ve-membered ring of the wild type Trp. Note that an
aromatic group is part of the Tyr-OnQ motif primarily
for synthetic reasons. It is not anticipated that a cation^
Z interaction is involved between the tethered quaternary
ammonium group and the aromatic of the side chain. The
tether of Tyr-OnQ must curve around to position the qua-
ternary ammonium above the site where the six-membered
ring of the natural Trp would be. Modeling indicates that
this is unlikely for a two-carbon tether, but is possible for
tethers of length = 3. Perhaps the tethers of Tyr-OnQ are
too long when n = 4 or 5, in£icting adverse steric interac-
tions when positioning the quaternary ammonium appro-
priately. The strong preference for a three-carbon tether at
position K149 suggests a fairly strict geometric require-
ment for achieving the maximum in constitutive activa-
tion.
We have also established that incorporation of tethered
agonists at two other sites creates a constitutively active
receptor. One of these sites is K93. Previous photoa⁄nity
and site-directed mutagenesis studies have suggested that
Tyr K93 is near the agonist binding site [6^8]. Our earlier
evaluation of this residue using unnatural amino acid mu-
tagenesis indicated that the OH of the Tyr forms an im-
portant hydrogen bond that a¡ects agonist binding; how-
ever, ACh is not the acceptor of this hydrogen bond [23].
As shown in Fig. 5, Tyr-OnQ with n = 2^5 are comparably
e¡ective at K93, in contrast to the results for K149.
The other site where tethered agonists lead to a consti-
tutively active receptor is Q55/N57. All the tethers with long
chains (v3 carbons) are modestly e¡ective at this site. This
suggests that Trp Q55/N57 must be fairly near the agonist
binding site. However, it is likely to be further away than
Trp K149 and Tyr K93, since the shortest tether is not
e¡ective. In fact, all tethers are less e¡ective at Trp Q55/
N57 than at the other sites.
We note that the constitutive currents (Fig. 4, a) are
consistently larger when Tyr-OnQ is incorporated at
K149 than at K93 and Q55/N57 (data not shown). This is
not simply because the receptor expresses more e⁄ciently
with the tether at K149, since the ratio of TMB-8-blocked
current to ACh-induced current shows the same trends.
Apparently, Tyr-OnQ is able to position the quaternary
ammonium more precisely and/or with less overall disrup-
tion of the receptor when it is delivered via K149 than K93
or Q55/N57.
Interesting results are seen with Tyr-O3tBu, a tether
that is isosteric to but lacks the positive charge of Tyr-
O3Q. No constitutively active or ACh-induced currents
are seen from e¡orts to incorporate Tyr-O3tBu at K149.
We noted above the challenges of interpreting negative
results from nonsense suppression experiments. However,
at the Trp K149 site we know that: (a) nonsense suppres-
sion can be quite e⁄cient if di¡erent unnatural amino
acids are employed; (b) a sterically very similar residue
(Tyr-O3Q) incorporates e⁄ciently; (c) the desired residue,
Tyr-O3tBu, does incorporate at other sites (see below) and
therefore is compatible with the ribosomal machinery.
Although not completely conclusive, e¡orts to determine
whether the receptor containing Tyr-O3tBu was success-
fully synthesized, assembled, and transported to the sur-
face suggest that it was not. For the reasons enumerated
above, we consider it unlikely that this represents a failure
of the nonsense suppression methodology. We think it
more likely that a receptor with Tyr-O3tBu incorporated
at position K149 does not fold or does not assemble prop-
erly, and therefore no receptor appears on the surface.
Thus, the immediate vicinity of the agonist binding site
^ the region very near Trp K149 ^ is quite sensitive, accept-
ing a very close analog of its natural ligand, Tyr-O3Q, but
nothing else.
At K93 and Q55/N57, Tyr-O3tBu is incorporated and
gives measurable constitutive currents, but less than the
cationic analog. While direct contact between ACh and
Trp K149 is well established, such is not the case for Tyr
K93 nor Trp Q55/N57. We propose that these ‘secondary’
sites are less intimately involved in de¢ning the agonist
binding site, but are better described as nearby. Incorpo-
rating the tether at these sites disrupts the binding region,
partly through a simple steric e¡ect, since Tyr-O3tBu
works. However, a tethered quaternary ammonium is
more e¡ective, suggesting these remote sites do sense
some of the binding interactions associated with the qua-
ternary ammonium on ACh.
It is important to appreciate that gating an ion channel
is a complex process. An agonist must bind to the receptor
and initiate opening of the ion channel. This is made even
more complicated in the nAChR, where the ion channel
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and its gate are structurally remote from the agonist bind-
ing site [9,27]. In such a system, it is envisioned that bind-
ing of agonist induces a conformational change that shifts
a pre-existing equilibrium between closed and open states
of the channel toward the open state. It is easy to imagine
that the structural perturbation of introducing Tyr-OnQ
or Tyr-O3tBu at one of the secondary sites could disrupt
the structure of the protein in the vicinity of the agonist
binding site in the direction of the conformational change
associated with opening. Note that in all cases the tethered
agonist is a weak agonist, indicating that the full e¡ect on
the open/closed equilibrium elicited by ACh is never
achieved with a tethered agonist. The tethered agonist es-
sentially pushes the receptor along the path toward open-
ing, or, stated di¡erently, perturbs the gating equilibrium,
but less e¡ectively than the true agonist. Precisely at the
agonist binding site, K149, the structural requirements are
more strict, and an optimal tether produces a large e¡ect.
Very recently, Sullivan and Cohen described tethered
agonist studies in which potential tethered agonists were
incorporated by reacting Cys residues introduced by site-
directed mutagenesis with various MTS reagents [21]. At
K149 the Cys mutation made the receptor unresponsive to
ACh, which is not surprising given the crucial role of Trp
K149 in agonist binding [12]. At K93, Cys modi¢cation
resulted in irreversible inhibition, while at Q55 there was
no e¡ect for the Cys mutants after treatment with MTS
reagents. Interestingly, though, reaction of the K198 Tyr/
Cys mutant with MTSET produced a constitutively active
receptor. This e¡ect was seen without the additional
Leu9PSer mutation required in the present studies, which
could indicate quite e⁄cient activation. The e¡ect at K198
was quite sensitive to the length and orientation of the
tethered group, in that lengthening or shortening the teth-
er by one methylene group negated the tethered agonist
e¡ect. The successful tether introduced by MTS modi¢ca-
tion (CKCH2SSCH2CH2NMe3 ) is much shorter than
those investigated here, and so our failure to see constitu-
tive activation with Tyr-OnQ at K198 is not surprising.
3.1. An emerging model of the agonist binding site of the
nAChR
E¡orts to develop a detailed picture of the agonist bind-
ing site of the nAChR continue in many labs. E¡orts to
date are schematized in Fig. 1. The binding site involves
several key residues located on several discontinuous
‘loops’. A large number of aromatic residues are associ-
ated with the agonist binding site, along with perhaps one
anionic residue. One residue in particular, Trp K149, has
been shown to contact the agonist in the binding site [12].
Another relevant observation is the high resolution crys-
tal structure of acetylcholine esterase (AChE) [28], the
only natural ACh binding site for which such a structure
is available. As was anticipated [29], a cation^Z interaction
is crucial for binding ACh. In fact, the esterase uses a
tryptophan, Trp 84, to bind the quaternary ammonium
group of ACh. In addition, the esterase features a 20 Aî
‘aromatic gorge’ that leads from the surface of the enzyme
to the active site and Trp 84. The gorge is lined with over
a dozen conserved aromatic residues that presumably
guide the ACh to the active site using cation^Z interac-
tions and other e¡ects. This structure was revealed at
about the same time that many workers were identifying
the large number of aromatic residues associated with the
agonist binding site of the nAChR. The possibility that a
comparable aromatic gorge would exist in the nAChR was
immediately apparent. Recently, Unwin has interpreted
electron densities in the vicinity of the agonist binding
site as consistent with such a gorge, but the images are
not yet of su⁄cient resolution to be decisive [9].
If an aromatic gorge analogous to the one found in the
AChE exists in the nAChR, then the results presented here
put certain constraints on the model, as summarized in
Fig. 7. Certainly, the bottom of the gorge and the ¢nal
resting place of ACh are de¢ned by Trp K149, playing the
role ascribed to Trp 84 in the esterase. Note that of all the
residues discussed as contributing to or being near the
agonist binding site (Fig. 1), evidence for direct interaction
with ACh exists only for Trp K149. The relatively strict
structural requirement at Trp K149 proposed here is con-
sistent with the absence of ACh response seen for the Cys
mutant at this site [21]. We propose that Tyr K93 is near
the bottom of the gorge, as evidenced by the fact that the
shortest tether elicits a response at this site. The OH of
Tyr K93 is involved in a key hydrogen bond in the binding
site, and we suggest this is a hydrogen bond to the protein
Fig. 7. The evolving view of the nAChR agonist binding site. Shown is
a highly schematic view of an ‘aromatic gorge’ analogous to that pro-
posed for ACh esterase. Trp K149 lies at the bottom of the gorge and
binds the quaternary ammonium group of ACh, playing the role of Trp
84 in the AChE. Tyr K198 is near the bottom of the gorge, while Tyr
K93 lies slightly up the gorge, and its OH forms an important hydrogen
bond. Trp Q55/N57 lies further up the gorge.
CHBIOL 52 7-2-01 Cyaan Magenta Geel Zwart
Research Paper Mapping the structure of nAChR by tethered agonists L. Li et al. 53
backbone [23]. Given that tethered agonists at Q55/N57 had
a weaker ability to open the channel and that the two-
carbon tether is ine¡ectual, we position Q55/N57 further
up the gorge. An ongoing debate in the nAChR literature
is whether the agonist binding site is best thought of as
being buried within the K subunits or whether it is at the
subunit interfaces, K/N and K/Q. Our results clearly support
a role for the Q/N subunits. However the K/N and K/Q
subunit interfaces might be contributing to the gorge lead-
ing to the agonist binding site, rather than actually struc-
turing the binding site. Finally, we include Tyr K198 as
very near the agonist binding site, based on the MTS
studies of Cohen. Of course, the model presented in Fig.
7 is highly speculative at this point, and we look forward
to further studies ^ both structural and mechanistic ^ to
re¢ne it.
4. Signi¢cance
In summary, we have shown that the tethered agonist
approach via unnatural amino acid mutagenesis is a gen-
eral tool for probing structure in the nAChR. We fully
expect it will be useful in other integral membrane pro-
teins. We have now positioned three residues ^ Trp K149,
Tyr K93 and Trp Q55/N57 ^ very near the agonist binding
site and each with a distinct role. We anticipate that fur-
ther application of this methodology will provide addition-
al, useful insights.
5. Materials and methods
5.1. Chemicals
Reagents were purchased from Aldrich, Sigma, or other com-
mercial sources. TMB-8 was purchased from RBI (Natick, MA,
USA). Anhydrous THF was distilled from sodium benzophe-
none; anhydrous methylene chloride, toluene and acetonitrile
were distilled from CaH2 ; anhydrous acetone was distilled from
CaSO4 ; anhydrous DMF was obtained from Fluka. Flash chro-
matography was on 230^400 mesh silica gel with the solvent in-
dicated. All NMR shifts are reported as N ppm down¢eld from
TMS. 1H NMR spectra were recorded at 300 MHz in CDCl3
using a GE QE-300 spectrometer. FAB-MS determinations
were performed at University of Nebraska-Lincoln. Electrospray
(ESI) ionization, quadrupole mass spectrometry was performed
at the Caltech Protein/Peptide Micro Analytical Laboratory.
High performance liquid chromatography (HPLC) separations
were performed on a Waters dual 510 pump liquid chromatog-
raphy system equipped with a Waters 490E variable wave-
length UV detector. Semi-preparative samples were separated us-
ing a Whatman Magnum 9 column (9.4U500 mm, Partisil 10,
ODS-3). Nitroveratryloxycarbonyl chloride (NVOC-Cl) and
NVOC-tyrosine t-butyl ester were prepared as described earlier
[23].
5.2. Synthesis of Tyr-OnQ
5.2.1. NVOC-O-(2-bromoethyl) tyrosine t-butyl ester (1a)
To a mixture of 0.690 ml (8 mmol, 16 equivalents) of
1,2-dibromoethane and 330 mg (1 mmol, two equivalents) of
Cs2CO3 in 15 ml of anhydrous DMF was added a solution of
238 mg (0.5 mmol) of NVOC-tyrosine t-butyl ester in 10 ml of
DMF slowly over 10 h using a syringe pump. After stirring over-
night, the reaction mixture was quenched by adding 30 ml of
water and extracted by 3U30 ml of ethyl acetate. The combined
organic layers were washed with water once, dried (over
Na2SO4), rotary-evaporated, and chromatographed (30:70 ethyl
acetate:petroleum ether), providing 61 mg (21%) of product.
1H NMR (CDCl3): N 7.69 (s, 1H), 7.05 (d, 2H), 6.95 (s, 1H),
6.81 (d, 2H), 5.54 and 5.46 (AB, 1H), 5.32 (d, 1H), 4.48
(m, 1H), 4.24 (t, 2H), 3.93 (s, 6H), 3.61 (t, 2H), 3.03 (m, 2H),
1.41 (s, 9H).
5.2.2. NVOC-O-(3-bromopropyl) tyrosine t-butyl ester (1b)
This compound was prepared by the procedure described
above. Yield 57%. 1H NMR (CDCl3): N 7.68 (s, 1H), 7.07 (d,
2H), 6.96 (s, 1H), 6.84 (d, 2H), 5.54 and 5.45 (AB, J = 15.2 Hz,
1H), 5.33 (d, 1H), 4.50 (m, 1H), 4.07 (m, 2H), 3.95 (s, 6H), 3.60
(t, 2H), 3.05 (m, 2H), 2.31 (m, 2H), 1.42 (s, 9H).
5.2.3. NVOC-O-(4-bromobutyl) tyrosine t-butyl ester (1c)
This compound was prepared by the procedure described
above. Yield 67%. 1H NMR (CDCl3): N 7.68 (s, 1H), 7.06 (d,
2H), 6.94 (s, 1H), 6.77 (d, 2H), 5.53 and 5.45 (AB, 1H), 5.35 (d,
1H), 4.46 (m, 1H), 3.94 (m, 2H), 3.92 (s, 6H), 3.46 (t, 2H), 3.01
(m, 2H), 2.02 (m, 2H), 1.90 (m, 2H), 1.40 (s, 9H).
5.2.4. NVOC-O-(5-bromopentyl) tyrosine t-butyl ester (1d)
This compound was prepared by the procedure described
above. Yield 58%. 1H NMR (CDCl3): N 7.52 (s, 1H), 6.94 (d,
2H), 6.82 (s, 1H), 6.65 (d, 2H), 5.61 (d, 1H), 5.32 (m, 2H), 4.35
(m, 1H), 3.96 (m, 2H), 3.77 (s, 6H), 3.28 (t, 2H), 2.91 (m, 2H),
1.77 (m, 2H), 1.65 (m, 2H), 1.40 (m, 2H), 1.27 (s, 9H).
5.2.5. NVOC-O-(4-bromobutyl) tyrosine cyanomethyl ester (2c)
To a solution of 290 mg (0.48 mmol) of azeotropically dried
(with toluene) NVOC-O-(1-(4-bromobutyl)) tyrosine t-butyl ester
in 1.7 ml of dry CH2Cl2 was slowly added 2.8 ml of TFA (37.2
mmol, 77.5 equivalents). The mixture was stirred under argon at
room temperature for 2 h. TFA was removed by passing argon
through the reaction solution. The residue was rotary-evaporated
with toluene twice (2U10 ml), dried under vacuum and then used
directly in the next step. To this crude product was added 5 ml of
anhydrous DMF, 0.67 ml (10.5 mmol, 21.8 equivalents) of chlo-
roacetonitrile and 96 Wl of diisopropylethylamine. The mixture
was stirred at room temperature overnight. After about 14 h
the reaction was quenched by adding 10 ml of 0.1 M KH2PO4
and 10 ml of water and then extracted with 2U50 ml of ethyl
acetate. The combined organic layers were washed with water,
dried (over Na2SO4) and rotary-evaporated. Flash chromatogra-
phy (1:3 to 2:3 ethyl acetate:petroleum ether) gave 210 mg (74%)
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of product. 1H NMR (CDCl3): N 7.66 (s, 1H), 7.03 (d, 2H), 6.89
(s, 1H), 6.80 (d, 2H), 5.51 and 5.41 (AB, 1H), 5.38 (d, 1H), 4.72
(m, 3H), 3.94 (m, 2H), 3.91 (s, 6H), 3.58 (t, 1H), 3.45 (t, 1H), 3.07
(m, 2H), 2.01 (m, 2H), 1.92 (m, 2H).
5.2.6. NVOC-O-(2-bromoethyl) tyrosine cyanomethyl ester (2a)
This compound was prepared by the procedure described
above. Yield 58%. 1H NMR (CDCl3): N 7.70 (s, 1H), 7.07 (d,
2H), 6.92 (s, 1H), 6.87 (d, 2H), 5.56 and 5.45 (AB, 1H), 5.29 (d,
1H), 4.76 (m, 3H), 4.27 (t, 2H), 3.95 (s, 6H), 3.63 (t, 2H), 3.10 (m,
2H).
5.2.7. NVOC-O-(3-bromopropyl) tyrosine cyanomethyl ester (2b)
This compound was prepared by the procedure described
above. Yield 93%. 1H NMR (CDCl3): N 7.66 (s, 1H), 7.04 (d,
2H), 6.90 (s, 1H), 6.83 (d, 2H), 5.54 and 5.45 (AB, J = 15.2 Hz,
1H), 5.46 (b, 1H), 4.74 (m, 3H), 4.06 (m, 2H), 3.93 (s, 6H), 3.57
(t, 2H), 3.08 (m, 2H), 2.28 (m, 2H).
5.2.8. NVOC-O-(5-bromopentyl) tyrosine cyanomethyl ester (2d)
This compound was prepared by the procedure described
above. Yield 69%. 1H NMR (CDCl3): N 7.61 (s, 1H), 7.01
(d, 2H), 6.86 (s, 1H), 6.77 (d, 2H), 5.53 (d, 1H), 5.46 and 5.37
(AB, 1H), 4.71 (m, 3H), 3.89 (m, 2H), 3.87 (s, 6H), 3.51 (t, 1H),
3.38 (t, 1H), 3.05 (m, 2H), 1.87 (m, 2H), 1.75 (m, 2H), 1.56
(m, 2H).
5.2.9. NVOC-O-(4-(N,N,N-trimethylammonium)butyl) tyrosine
cyanomethyl ester (NVOC-Tyr-O4Q) (3c)
200 mg (0.337 mmol) of NVOC-O-(1-(4-bromobutyl)) tyrosine
cyanomethyl ester was mixed with 650 mg (4.333 mmol, 12.5
equivalents) of sodium iodide in 10 ml of acetone at room tem-
perature. The reaction was kept stirring in the dark overnight.
Acetone was then rotary-evaporated o¡, and the solid was par-
titioned between water and methylene chloride (30 ml each). The
aqueous layer was extracted with methylene chloride once. Or-
ganic layers were combined, washed with water once, dried (over
Na2SO4), and rotary-evaporated to give 200 mg (93%) of yellow-
ish solid NVOC-O-(1-(4-iodobutyl)) tyrosine cyanomethyl ester.
Half of this product was carried on to make NVOC-O-(1-(4-
(N,N,N-trimethylammonium)-butyl)) tyrosine cyanomethyl ester.
The solution of the iodide in 7 ml of dry toluene and 12 ml of dry
THF was cooled to 0‡C in an ice/NaCl bath. Then trimethyl-
amine was passed through the solution via a metal needle for
about 5 min. The solution was allowed to warm up to room
temperature and stirred in the dark for 32 h. Precipitate formed
on the inner wall of the £ask. Argon was passed through to get
rid of the amine, which was trapped by 6 N HCl. When most of
the amine was removed (indicated as neutral by wet pH paper),
the solution was decanted and the solid was rinsed with ethyl
acetate three times and dried under vacuum. Yield 70 mg
(68%). 1H NMR (CDCl3): N 7.74 (s, 1H), 7.23 (d, 2H), 7.13
(s, 1H), 6.91 (d, 2H), 6.46 (d, 1H), 5.46 and 5.39 (AB, 1H),
4.85 (s, 2H), 4.52 (m, 1H), 4.05 (t, 2H), 3.96 (s, 3H), 3.93
(s, 3H), 3.39 (m, 2H), 3.10 (s, 9H), 3.00 (m, 2H), 1.98 (m, 2H),
1.85 (m, 2H).
5.2.10. NVOC-O-(2-(N,N,N-trimethylammonium)ethyl) tyrosine
cyanomethyl ester (NVOC-Tyr-O2Q) (3a)
This compound was prepared by the procedure described
above. Yield 85%. 1H NMR (CDCl3): N 7.73 (s, 1H), 7.26 (d,
2H), 7.11 (s, 1H), 6.94 (d, 2H), 6.41 (d, 1H), 5.44 and 5.37 (AB,
1H), 4.83 (s, 2H), 4.55 (m, 1H), 4.41 (m, 2H), 3.95 (s, 3H), 3.92 (s,
3H), 3.74 (m, 2H), 3.20 (s, 9H), 3.01 (m, 2H).
5.2.11. NVOC-O-(3-(N,N,N-trimethylammonium)propyl)
tyrosine cyanomethyl ester (NVOC-Tyr-O3Q) (3b)
This compound was prepared by the procedure described
above. Yield 85%. 1H NMR (CDCl3): N 7.72 (s, 1H), 7.22 (d,
2H), 7.09 (s, 1H), 6.88 (d, 2H), 6.36 (b, 1H), 5.54 and 5.45 (AB,
J = 15.2, 1H), 4.82 (s, 2H), 4.50 (m, 1H), 4.07 (m, 2H), 3.95 (s,
3H), 3.90 (s, 3H), 3.47 (t, 2H), 3.08 (m, 9H), 2.98 (m, 2H), 2.00^
2.10 (shoulder, 2H).
5.2.12. NVOC-O-(5-(N,N,N-trimethylammonium)pentyl)
tyrosine cyanomethyl ester (NVOC-Tyr-O5Q) (3d)
This compound was prepared by the procedure described
above. Yield 74%. 1H NMR (CDCl3): N 7.72 (s, 1H), 7.20 (d,
2H), 7.11 (s, 1H), 6.87 (d, 2H), 6.47 (d, 1H), 5.44 and 5.37 (AB,
1H), 4.83 (s, 2H), 4.51 (m, 1H), 4.00 (t, 2H), 3.92 (s, 3H), 3.90 (s,
3H), 3.31 (m, 2H), 3.13 (m, 2H), 3.08 (s, 9H), 1.98 (m, 2H), 1.83
(m, 2H), 1.53 (m, 2H).
5.3. Synthesis of Tyr-O3tBu
5.3.1. 4,4P-Dimethylpentanol (5)
To a solution of 2 ml (13.9 mmol) 4,4Pdimethylpentene in 6 ml
of anhydrous THF at 378‡C was added 13.9 ml of a 1 M BH3^
THF complex solution over 10 min via a syringe pump. The
reaction mixture was stirred at 378‡C for 45 min, then allowed
to warm to room temperature and stirred for an additional 45
min. The reaction mixture was cooled to 0‡C and 1.39 ml H2O,
1.86 ml 3 M NaOH, and 2.5 ml 30% H2O2 were added. The
solution was stirred for 72 h, extracted with 25 ml ether, and
washed with 2U5 ml ice-cold H2O followed by 2U5 ml saturated
NaCl salt solution. The organic layer was dried over MgSO4 and
rotary-evaporated to give 1.124 g (70% yield). 1H NMR (CDCl3):
N 7.31 (s, 1H), 3.77 (t, 2H), 1.58 (m, 2H), 1.27 (m, 2H), 0.93 (s,
9H).
5.3.2. 4,4P-Dimethyl pentyl tosylate (6)
To a solution of 957 mg (8.25 mmol) 4,4P-dimethylpentanol in
8 ml anhydrous pyridine at 0‡C was added 3.15 g (16.5 mmol) p-
toluene sulfonyl chloride. The reaction mixture was slowly
warmed to room temperature and stirred for 36 h. The reaction
mixture was poured over 3 g ice and extracted with 6U5 ml
dichloromethane, 6U5 ml ether, and 6U5 ml chloroform. The
organic layers were washed using 2U1 ml 6 N HCl, 2U1 ml
saturated NaHCO3 salt solution, and 2U1 ml saturated NaCl
salt solution. The organic layers were combined, dried over
MgSO4, and concentrated under vacuum to give 1.106 g (49.6%
yield). The product was puri¢ed by £ash chromatography (30:70
ethyl acetate:petroleum ether) to give 174.2 mg. 1H NMR
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(CDCl3): N 7.75 (d, 2H), 7.31 (d, 2H), 3.98 (t, 2H), 2.39 (s, 3H),
1.53 (m, 2H), 1.12 (m, 2H), 0.78 (s, 9H).
5.3.3. NVOC-O-(4,4P-dimethyl pentyl) tyrosine t-butyl ester (7)
To a mixture of 486 mg (3.52 mmol) K2CO3 and 115.6 mg
(0.243 mmol) NVOC-tyrosine t-butyl ester in 1 ml of anhydrous
acetone was added a solution of 65.6 mg (0.243 mmol) 4,4P-di-
methylpentyl tosylate in 1.5 ml anhydrous acetone. Another 2.4
ml anhydrous acetone was added to reaction mixture via a sy-
ringe to bring the total volume of solvent to 4.9 ml. The reaction
mixture was re£uxed for 60 h, quenched with 15 ml water, and
extracted with 4U10 ml ether. The organic layers were combined,
dried under MgSO4, and concentrated by rotary evaporation.
The product was puri¢ed by £ash chromatography (20:80 ethyl
acetate:petroleum ether) to give approximately 60 mg (V40%
yield). 1H NMR (CDCl3): N 7.68 (s, 1H), 7.03 (d, 2H), 6.95 (s,
1H), 6.80 (d, 2H), 5.48 (m, 2H), 5.28 (d, 1H), 4.70 (m, 1H), 3.92
(m, 6H), 3.85 (m, 2H), 3.04 (t, 2H), 1.73 (m, 2H), 1.40 (s, 9H),
1.26 (m, 2H), 0.89 (s, 9H).
5.3.4. NVOC-O-(4,4P-dimethyl pentyl) tyrosine cyanomethyl ester
(8)
To a solution of 60 mg of the above product in 2 ml dichloro-
methane was added 1 ml TFA and stirred for 1 h. The TFA was
removed under vacuum. The product was puri¢ed by £ash chro-
matography using CH2Cl2 followed by CH2Cl2 with 1% acetic
acid. The product was concentrated by rotary evaporation and
then dissolved in 3 ml DMF. To the solution 0.6 ml chloroace-
tonitrile (9.5 mmol) and 16 Wl triethylamine were added, and the
reaction mixture was allowed to stir for 2 days. The reaction was
quenched with 10 ml 0.1 M potassium phosphate solution and 20
ml H2O. The product was extracted with 3U30 ml CH2Cl2, dried
over NaSO4, and concentrated under vacuum. The product was
puri¢ed by £ash chromatography (20:80 ethyl acetate:petroleum
ether) to give approximately 20 mg (V65% yield). 1H NMR
(CDCl3): N 7.68 (s, 1H), 7.02 (d, 2H), 6.90 (s, 1H), 6.84 (d,
2H), 5.46 (m, 2H), 5.28 (d, 1H), 4.77 (s, 2H), 4.70 (m, 1H),
3.93 (m, 6H), 3.86 (m, 2H), 3.07 (d, 2H), 1.73 (m, 2H), 1.27
(m, 2H), 0.90 (s, 9H).
5.4. General procedure for coupling of amino acid to dCA
This method is essentially as described [22,23]. The N-pro-
tected amino acid (V30 Wmol, three equivalents) was mixed
with tetra-n-butyl-ammonium salt of the dCA dinucleotide
(V10 Wmol, one equivalent) in 400 Wl of dry DMF. The reaction
mixtures are kept stirring for 1^2 h. The crude product was sep-
arated using reverse-phase semi-preparative HPLC with a gra-
dient from 25 mM ammonium acetate (pH 4.5) to CH3CN.
The desired fractions containing the aminoacyl dinucleotide
were combined, frozen, and lyophilized. The lyophilized solid
was redissolved in 10 mM aqueous acetic acid/acetonitrile and
lyophilized a second time to remove salts. The products were




Prepared as above: FAB-MS: [M], calculated for
C43H56N11O21P2 : 1124.3128; found: 1124.2.
5.4.2. dCA-NVOC-O-(1-(3-(N,N,N-trimethylammonium)-
propyl)) tyrosine (dCA-Tyr-O3Q) (4b)
Prepared as above: FAB-MS: [M], calculated for
C44H57N11O21P2 : 1137.5; found: 1137.
5.4.3. dCA-NVOC-O-(1-(4-(N,N,N-trimethylammonium)butyl))
tyrosine (dCA-Tyr-O4Q) (4c)
Prepared as above: FAB-MS: [M], calculated for
C45H60N11O21P2 : 1152.3440; found: 1152.3.
5.4.4. dCA-NVOC-O-(1-(5-(N,N,N-trimethylammonium)pentyl))
tyrosine (dCA-Tyr-O5Q) (4d)
Prepared as above: FAB-MS: [M], calculated for
C46H62N11O21P2 : 1166.3596; found: 1166.4.
5.4.5. dCA-NVOC-O-(4,4P-dimethyl pentyl) tyrosine
(dCA-Tyr-O3tBu) (9)
Prepared as above except that a catalytic amount of tetrabu-
tylammonium acetate was added to the reaction mixture. ESI-
MS; calculated for C45H57N10O21P2 : 1135.3175; found [M-H]3
1135.72.
5.5. Unnatural amino acid mutagenesis and oocyte injection
The site-directed mutagenesis of the nAChR TAG mutants,
gene construction and synthesis of suppressor tRNA and ligation
of aminoacyl-dCA to tRNA have been described previously [1^
3,30]. Plasmid DNAs were linearized with NotI, and mRNA was
transcribed using the Ambion (Austin, TX, USA) T7 mMES-
SAGE mMACHINE kit.
Oocytes were removed from Xenopus laevis as described [31]
and maintained at 18‡C, in ND96 solution (96 mM NaCl/2 mM
KCl/1.8 mM CaCl2/1 mM MgCl2/5 mM HEPES/2.5 mM sodium
pyruvate/0.5 mM theophyline/10 g/ml gentamicin, pH 7.5, with
NaOH). Before microinjection, the NVOC-aminoacyl-tRNA was
deprotected by irradiating the sample for 5 min with a 1000 W
xenon arc lamp (Oriel) operating at 600 W equipped with WG-
335 and UG-11 ¢lters (Schott, Duryea, PA, USA). Each oocyte
was injected with a 1:1 mixture of deprotected aminoacyl-tRNA
(25^50 ng) and mRNA (12.5^18 ng of total at a concentration
ratio of 20:1:1:1 for K :L :Q :N subunits) in a volume of 50 nl. Since
the presence of constitutively active channels would be expected
to compromise the health of the oocytes through a large leak
current, 2^5 WM TMB-8 was added to the incubation solution
to block any leak current that might occur through the nAChR.
5.6. Electrophysiology
Electrophysiological recordings were carried out 24^48 h after
injection. Whole-cell currents from oocytes were measured using
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a Geneclamp 500 ampli¢er and pCLAMP software (Axon Instru-
ments, Foster City, CA, USA) in the two-electrode voltage-clamp
con¢guration. Microelectrodes were ¢lled with 3 M KCl and had
resistances ranging from 0.5 to 1.5 M6. Oocytes were continu-
ously perfused with a nominally calcium-free bath solution con-
sisting of 96 mM NaCl, 2 mM KCl, 1 mM MgCl2; and 5 mM
HEPES (pH 7.5). Microscopic ACh-induced and TMB-8-blocked
currents were recorded in response to bath application of ACh
(25 WM) and TMB-8 (5 WM or 10 WM) at a holding potential of
380 mV. All numerical and plotted data are from measurements
obtained from 4^8 oocytes and are reported as mean þ S.E.M.
5.7. Bungarotoxin binding and Western blot analysis
[125I]Bungarotoxin binding experiments were performed as de-
scribed [32]. Oocytes were incubated in 400 Wl of calcium-free
ND96 (see Section 5.6) containing 10 mg/ml bovine serum albu-
min (Sigma) for 10 min and then [125I]bungarotoxin (Amersham)
was added to a ¢nal concentration of 1 nM. After incubation for
2 h, the oocytes were washed extensively and then counted in a
Beckman LS5000 Q-counter.
Western blot analyses were carried out as described [33]. A
hemagglutinin (HA) epitope was subcloned into the intracellular
loop between the third and fourth transmembrane domains of the
K subunit. The vitelline/plasma membranes were manually
stripped from oocytes expressing nAChR [34]. Alternatively, the
oocytes were treated with sulfo-NHS-LC-biotin (Pierce) and then
homogenized. After removing the yolks of the oocytes by a cen-
trifuge, the remaining supernatant was incubated with streptavi-
din-agarose beads (Sigma). The protein was then eluted from the
beads by adding sodium dodecyl sulfate (SDS) bu¡er. In either
case, the samples were analyzed by SDS^PAGE, followed by
immunoblotting with the anti-HA antibody (BabCO, cat. #
MMS-101R), and visualized using an ECL detection kit (Amer-
sham).
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